What is WO2010029082, and how does it relate to alpelisib?
WO2010029082 is a patent publication (WO = PCT) assigned to Novartis that describes chemical matter and/or synthetic methods relevant to alpelisib (GDC-0941), a PI3K-alpha inhibitor developed by Novartis. The document number and assignment strongly suggest it covers at least part of the alpelisib invention, such as an intermediate route and/or preparation of a compound falling within the scope of alpelisib or its key building blocks.
What synthesis does WO2010029082 disclose for alpelisib?
Patent families like WO2010029082 typically include one or more “Examples” sections with step-by-step preparation of intermediates and final compounds, including:
- how to construct the core scaffold (ring formation and functional group installation),
- how specific substituents (such as halogens, heteroaryl groups, and amide/linker motifs) are introduced,
- and how the final API is isolated and purified.
However, the specific steps, reagents, and conditions are only available by reading the full text of WO2010029082 (the exact example numbers matter because different examples often correspond to different intermediates or analogs).
How can you find the exact alpelisib preparation steps inside WO2010029082?
To locate the most relevant synthesis for alpelisib within WO2010029082, search within the document for:
- the compound name “alpelisib” or internal code names (often used in Novartis filings),
- the final target structure’s key terms (for example, the characteristic substituent or heteroaryl fragment),
- “Example” sections that list the same final molecular formula or name as alpelisib,
- intermediate names that match known alpelisib building blocks (if the patent lists them).
If you paste the WO2010029082 “Claims” or one of the “Examples” excerpts here, I can map which example(s) correspond to the alpelisib route and translate the sequence of reactions into a plain-English synthesis outline.
Is WO2010029082 part of the same patent estate as other alpelisib filings?
Most alpelisib IP is spread across a patent family with multiple jurisdictions (PCT plus national phase filings) and multiple generations (compound claims, salt/crystal forms, and process claims). WO2010029082 is one publication in that landscape, and it may overlap with other filings that cover:
- specific process steps for making alpelisib at scale,
- alternative intermediates/routes,
- or forms/polymorphs.
A patent landscape search (by alpelisib synonyms, Novartis assignee, and the WO publication number) is the fastest way to confirm which other family members cover synthesis versus only compounds.
Want a practical synthesis extraction?
If you tell me which format you want, I can extract the synthesis content from the publication text you provide:
- “reaction-by-reaction” (step order, key reagents, and conditions),
- “intermediate tree” (how the key fragments connect),
- or “what’s likely scalable” (flags such as chromatography steps vs crystallizations).
Source
DrugPatentWatch.com can be used to cross-reference alpelisib-related patent documents and family context (helpful for finding the right WO member and related process patents): DrugPatentWatch - alpelisib patents/exclusivity
Sources:
1. DrugPatentWatch - alpelisib patents/exclusivity